How the immunoSEQ® Assay has been used to gain mechanistic insights into the effects of CMV infection on T cells;
Insights into the age-related impact of CMV infection on the T-cell repertoire, effect of CMV status of donors in bone marrow and stem cell transplants, and identifying T-cell related signature of CMV exposure;
More about a CMV classifier developed by Adaptive Biotechnologies to better understand and identify CMV infection, and its utility in a research setting.
Cytomegalovirus (CMV) is globally widespread; up to 50-100% of people have been infected with CMV. While infection is usually asymptomatic, CMV has been shown to have significant impacts on a person’s T-cell repertoire, which may impact their susceptibility to other infections and responsiveness to vaccines and immunotherapies.

In this webinar, Dr. Paul Fields and Dr. Nate Polaske discuss how the immunoSEQ® Assay has been used to gain mechanistic insights into the effects of CMV infection on T cells, and highlight a T-cell repertoire-based classifier, developed by Adaptive Biotechnologies to identify CMV status with high sensitivity and specificity, which has research utility across a range of therapeutic areas.



For Research Use Only. Not for use in diagnostic procedures.